Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MMQNO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-PNU-159682
|
|||||
| Synonyms |
Trastuzumab-BCN-HydraSpace-Val-Cit-PABC-PNU-159682
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.81
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
PNU-159682
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
BCN-HydraSpace-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
GlycoConnect technology uses the globally conserved N-glycosylation site (Asn 279) to generate stable and site-specific ADCs based on enzymatic remodeling (engineered endoglycosidase and native glycosyl transferase).
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.